Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director | April 20, 2026 | April 21, 2026 |
| Outset Medical, Inc.OM · Entity 7026 | Chief Financial Officer | June 24, 2021 | June 25, 2021 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Financial Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 20, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Other · Disposed 140,612 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 140,612 |
Reported balance
After 2026-04-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-20 · Other · Acquired 140,612 · Balance 140,612 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Outset Medical, Inc.
Report date June 24, 2021 · Filed June 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,597 |
Ending reported balance
After 2021-06-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-24 · Exercise / conversion · Acquired 16,727 · Balance 30,324 Row 2 · 2021-06-24 · Sale · Disposed 16,727 · Balance 13,597 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.32 to $51.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2029-09-10 | Direct | 77,745 |
Reported balance
After 2021-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-24 · Exercise / conversion · Disposed 16,727 · Balance 77,745 F3: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.32 to $51.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date.
VERACYTE, INC.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,025 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-02 · Tax withholding · Disposed 3,603 · Balance 169,677 F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Row 2 · 2026-09-04 · Sale · Disposed 2,477 · Balance 167,200 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 3 · 2026-09-04 · Sale · Disposed 1,175 · Balance 166,025 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4: Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
F3: Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F4: Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 9,684 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,175 | $43.71 | $51,363.95 |
DisclosureSEC source: 0001823563-26-000016 · wk-form4_1788566045.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,025 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,477 | $42.81 | $106,030.21 |
DisclosureSEC source: 0001823563-26-000016 · wk-form4_1788566045.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,200 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,603 | $44.88 | $161,702.64 |
DisclosureSEC source: 0001823563-26-000016 · wk-form4_1788566045.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,677 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 01:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,961 | $50.09 | $98,229.04 |
DisclosureSEC source: 0001823563-26-000014 · wk-form4_1780623518.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,280 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.88 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 01:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,600 | $49.28 | $78,853.76 |
DisclosureSEC source: 0001823563-26-000014 · wk-form4_1780623518.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,241 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.80 to $49.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 02, 2026 Filed Jun 5, 2026 01:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,693 | $47.80 | $176,525.40 |
DisclosureSEC source: 0001823563-26-000014 · wk-form4_1780623518.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,841 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:37 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 140,612 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001823563-26-000013 · form4-04212026_120444.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,612 Underlying: Common Stock · 140,612 shares Expires 2036-01-14 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:37 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 140,612 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001823563-26-000013 · form4-04212026_120444.xml · derivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 140,612 shares Expires 2036-01-14 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 13,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001823563-26-000008 · wk-form4_1773176995.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,534 F2 · kind: Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 36,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001823563-26-000008 · wk-form4_1773176995.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,377 F1 · kind: Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 13,941 | $36.33 | $506,459.80 |
DisclosureSEC source: 0001823563-26-000006 · wk-form4_1772832781.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,196 F1 · kind: The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $36.01 to $36.55. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,400 | $35.55 | $156,409.44 |
DisclosureSEC source: 0001823563-26-000006 · wk-form4_1772832781.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,137 F1 · kind: The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 7,234 | $36.01 | $260,496.34 |
DisclosureSEC source: 0001823563-26-000004 · wk-form4_1772659015.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,537 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:53 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 12,049 | $38.75 | $466,898.75 |
DisclosureSEC source: 0001823563-26-000002 · wk-form4_1772488380.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,771 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:53 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 59,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001823563-26-000002 · wk-form4_1772488380.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,820 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 26, 2026, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Of such PSUs, 23,411 PSUs vested on February 26, 2026, and the remaining 35,913 will vest on December 2, 2026, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 00:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,741 | $47.25 | $224,008.93 |
DisclosureSEC source: 0001823563-25-000007 · wk-form4_1764895449.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,496 F2 · kind: The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.05 to $47.51. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 00:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 8,537 | $46.61 | $397,946.28 |
DisclosureSEC source: 0001823563-25-000007 · wk-form4_1764895449.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,237 F2 · kind: The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.04 to $47.03. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,384 | $46.16 | $156,205.44 |
DisclosureSEC source: 0001823563-25-000007 · wk-form4_1764895449.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,774 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on December 2, 2025 and does not represent a sale. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 7,000 | $41.00 | $287,000.00 |
DisclosureSEC source: 0001823563-25-000005 · wk-form4_1762549809.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,158 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 5,371 | $30.11 | $161,720.81 |
DisclosureSEC source: 0001384101-25-000122 · wk-form4_1757022311.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,158 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 5,370 | $26.74 | $143,593.80 |
DisclosureSEC source: 0001384101-25-000071 · wk-form4_1749070882.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,529 F1 · kind: The reporting person is reporting the withholding of 1,080, 658, 906, 826 and 1,900 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,295, 1,784, 1,626 and 3,741 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 30,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000043 · wk-form4_1741639435.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,899 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 11,070 | $34.76 | $384,793.20 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,699 F3 · kind: The reporting person is reporting the withholding of 1,080, 659, 906, 826 and 7,599 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,296, 1,783, 1626 and 14,964 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 11,911 | $33.84 | $403,068.24 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,769 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 23,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,680 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 19:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 9,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005730 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 527 | $43.85 | $23,108.95 |
DisclosureSEC source: 0001384101-25-000006 · wk-form4_1738792155.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,510 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:59 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 7,000 | $43.23 | $302,621.90 |
DisclosureSEC source: 0001384101-24-000180 · wk-form4_1733349562.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,037 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.71 to $43.64. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:59 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,464 | $44.12 | $152,831.68 |
DisclosureSEC source: 0001384101-24-000180 · wk-form4_1733349562.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,037 F1 · kind: The reporting person is reporting the withholding of 1,077, 657, 905 and 825 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,295, 1,784 and 1,626 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,275 | $38.34 | $585,663.36 |
DisclosureSEC source: 0001384101-24-000166 · wk-form4_1731620149.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,501 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $38.04 to $38.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:24 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,464 | $31.55 | $109,289.20 |
DisclosureSEC source: 0001384101-24-000151 · wk-form4_1725491088.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,776 F1 · kind: The reporting person is reporting the withholding of 1,077, 657, 905 and 825 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,296, 1,784 and 1,626 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 17:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 260 | $45.99 | $11,957.40 |
DisclosureSEC source: 0001127602-24-019169 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,684 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. Read SEC document |
| June 02, 2024 Filed Jun 4, 2024 20:43 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,462 | $20.75 | $71,836.50 |
DisclosureSEC source: 0001384101-24-000079 · wk-form4_1717533798.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,240 F1 · kind: The reporting person is reporting the withholding of 1,077, 657, 904 and 824 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,295, 1,783 and 1,625 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| May 20, 2024 Filed May 21, 2024 18:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 964 | $45.39 | $43,755.96 |
DisclosureSEC source: 0001127602-24-016184 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,944 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 16:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-013465 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,908 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,189 | $21.10 | $46,187.90 |
DisclosureSEC source: 0001384101-24-000045 · wk-form4_1710881393.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,702 F2 · kind: The reporting person is reporting the withholding of 2,189 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 4,189 Performance Stock Units vested on March 15, 2024 and does not represent a sale by the reporting person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 4,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000045 · wk-form4_1710881393.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,891 F1 · kind: Represents the acquisition of restricted stock units ("RSUs") earned by the Reporting Person upon the achievement of performance goals for the one-year period ended December 31, 2023, as reflected in the financial statements and certified by the Compensation Committee of the Board of Directors on March 15, 2024. The RSUs vested March 15, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 59,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000037 · wk-form4_1709933786.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,573 F1 · kind: Restricted stock units awarded on March 6, 2024 vest 25% on March 2, 2025 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 22:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 6,112 | $24.00 | $146,688.00 |
DisclosureSEC source: 0001384101-24-000026 · wk-form4_1709677679.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,717 F1 · kind: The reporting person is reporting the withholding of 1,190, 726, 900 and 3,296 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,296, 1,784 and 6,503 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, and March 6, 2023, respectively, and does not represent a sale by the reporting person. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 21:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,800 | $26.54 | $47,772.00 |
DisclosureSEC source: 0001384101-23-000169 · wk-form4_1701812679.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,829 F1 · kind: The reporting person is reporting the withholding of 735, 448 and 617 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,295 and 1,783 Restricted Stock Units granted on July 19, 2021, March 3, 2022 and August 5, 2022, respectively, and does not represent a sale by the reporting person. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 20:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,652 | $26.70 | $97,508.40 |
DisclosureSEC source: 0001384101-23-000147 · wk-form4_1694032228.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,629 F1 · kind: The reporting person is reporting the withholding of 735, 449 and 2,468 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,296 and 7,135 Restricted Stock Units granted on July 19, 2021, March 3, 2022 and August 5, 2022, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 527 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,183 | $26.72 | $31,609.76 |
DisclosureSEC source: 0001384101-23-000082 · wf-form4_168608452858125.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,754 F1 · kind: The reporting person is reporting the withholding of 735 and 448 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125 and 1,295 Restricted Stock Units granted on July 19, 2021 and March 3, 2022, respectively, and does not represent a sale by the reporting person. Read SEC document |
| May 18, 2023 Filed May 19, 2023 17:55 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 2,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016351 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,782 F1 · shares: Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting. Read SEC document |
| March 06, 2023 Filed Mar 10, 2023 00:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 42,956 | $0.00 Strike: $23.73 | $0.00 |
DisclosureSEC source: 0001384101-23-000035 · wf-form4_167840697137017.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,956 Underlying: Common Stock · 42,956 shares Expires 2033-03-06 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2024, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 06, 2023 Filed Mar 10, 2023 00:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 26,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000035 · wf-form4_167840697137017.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,937 F1 · kind: Restricted stock units awarded on March 6, 2023 vest 25% on March 2, 2024 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:11 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,726 | $24.10 | $65,696.60 |
DisclosureSEC source: 0001384101-23-000030 · wf-form4_167789226146411.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,923 F1 · kind: The reporting person is reporting the withholding of 867 and 1,859 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125 and 5,182 Restricted Stock Units granted on July 19, 2021 and March 3, 2022, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 651 shares of common stock purchased on January 31, 2023 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:14 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 735 | $29.14 | $21,417.90 |
DisclosureSEC source: 0001384101-22-000153 · wf-form4_167036483697035.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,998 F1 · kind: The reporting person is reporting the withholding of 735 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125 Restricted Stock Units granted on July 19, 2021 and does not represent a sale by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:56 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,023 | $19.18 | $57,981.14 |
DisclosureSEC source: 0001384101-22-000129 · wf-form4_166258416622084.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,733 F1 · kind: The reporting person is reporting the withholding of 3,023 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 8,500 Restricted Stock Units granted on July 19, 2021 and does not represent a sale by the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock · Derivative | 36,496 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0001384101-22-000115 · wf-form4_166007981918123.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,496 Underlying: Stock Option (right to buy) · 36,496 shares Expires 2032-08-05 F3 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares on August 5, 2023, and the remaining shares vest at a rate of 1/36th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 21,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000115 · wf-form4_166007981918123.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,756 F1 · kind: Restricted stock units awarded on August 5, 2022 vest 1/3rd on September 2, 2023 and 1/12th per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. F2 · balance_after: Includes 624 shares of common stock purchased on July 29, 2022 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.